Application of Human Three-Dimensional Multicellular Models for Personalized Cancer Therapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (31 December 2024) | Viewed by 3458
Special Issue Editor
Interests: personalized cancer therapy; functional diagnostics; cancer modeling; patient-derived cancer spheroids; innovative treatment options
Special Issue Information
Dear Colleagues,
Personalized cancer therapy based on individual tumor characteristics is playing an increasingly important role in cancer treatment. Currently, personalized oncology is mainly defined as the molecular profiling of tumors to select a targeted therapy for the individual cancer patient. However, a significant number of cancer patients do not benefit from this treatment selection strategy. This highlights the need to consider additional tumor characteristics relevant to drug response and to incorporate additional testing systems beyond the evaluation of genetic information into the treatment decision process.
The Special Issue "Application of Three-Dimensional Human Multicellular Models for Personalized Cancer Therapy" aims to provide an update on complex 3D human cancer models such as organoids, spheroids, tissue cultures, on-a-chip platforms, bioprinted models, and microfluidic systems developed for drug selection for individual cancer patients.
Dr. Barbara Mayer
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- complex human 3D cancer models
- patient-derived 3D cancer models
- functional diagnostics
- personalized therapy
- efficacy testing
- toxicity testing
- automated drug selection
- combined drug selection strategies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
